These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27322916)

  • 21. Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
    Prechtl A; Harbeck N; Thomssen C; Meisner C; Braun M; Untch M; Wieland M; Lisboa B; Cufer T; Graeff H; Selbmann K; Schmitt M; Jänicke F
    Int J Biol Markers; 2000; 15(1):73-8. PubMed ID: 10763145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
    Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
    Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
    Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C
    Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
    Duffy MJ
    Clin Chem; 2002 Aug; 48(8):1194-7. PubMed ID: 12142372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
    Kantelhardt EJ; Vetter M; Schmidt M; Veyret C; Augustin D; Hanf V; Meisner C; Paepke D; Schmitt M; Sweep F; von Minckwitz G; Martin PM; Jaenicke F; Thomssen C; Harbeck N
    BMC Cancer; 2011 Apr; 11():140. PubMed ID: 21496284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
    Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Jänicke F; Schmitt M; Pache L; Ulm K; Harbeck N; Höfler H; Graeff H
    Breast Cancer Res Treat; 1993; 24(3):195-208. PubMed ID: 8435475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
    Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
    Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel machine learning-derived decision tree including uPA/PAI-1 for breast cancer care.
    Reix N; Lodi M; Jankowski S; Molière S; Luporsi E; Leblanc S; Scheer L; Ibnouhsein I; Benabu JC; Gabriele V; Guggiola A; Lessinger JM; Chenard MP; Alpy F; Bellocq JP; Neuberger K; Tomasetto C; Mathelin C
    Clin Chem Lab Med; 2019 May; 57(6):901-910. PubMed ID: 30838840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
    Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
    Deluche E; Venat-Bouvet L; Leobon S; Fermeaux V; Mollard J; Saidi N; Jammet I; Aubard Y; Tubiana-Mathieu N
    BMC Cancer; 2017 Sep; 17(1):662. PubMed ID: 28954632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
    Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
    Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.
    Cufer T; Borstnar S; Vrhovec I
    Int J Biol Markers; 2003; 18(2):106-15. PubMed ID: 12841679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    Hall PS; McCabe C; Stein RC; Cameron D
    J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
    Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.